DOCSLIB.ORG

Prescribing Drugs of Dependence in General Practice, Part B – Benzodiazepines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescribing Drugs of Dependence in General Practice, Part B – Benzodiazepines H C 3 O N CI N Prescribing drugs of dependence N in general practice, Part B CH 3 Benzodiazepines N N H C 3 O O N H N CI N OH CI N CI N H C 3 O CI N O2N N O H N F www.racgp.org.au Healthy Profession. OH Healthy Australia. CI N CI Prescribing drugs of dependence in general practice, Part B – Benzodiazepines Disclaimer The information set out in this publication is current at the date of first publication and is intended for use as a guide of a general nature only and may or may not be relevant to particular patients or circumstances. Nor is this publication exhaustive of the subject matter. Persons implementing any recommendations contained in this publication must exercise their own independent skill or judgement or seek appropriate professional advice relevant to their own particular circumstances when so doing. Compliance with any recommendations cannot of itself guarantee discharge of the duty of care owed to patients and others coming into contact with the health professional and the premises from which the health professional operates. Whilst the text is directed to health professionals possessing appropriate qualifications and skills in ascertaining and discharging their professional (including legal) duties, it is not to be regarded as clinical advice and, in particular, is no substitute for a full examination and consideration of medical history in reaching a diagnosis and treatment based on accepted clinical practices. Accordingly, The Royal Australian College of General Practitioners and its employees and agents shall have no liability (including without limitation liability by reason of negligence) to any users of the information contained in this publication for any loss or damage (consequential or otherwise), cost or expense incurred or arising by reason of any person using or relying on the information contained in this publication and whether caused by reason of any error, negligent act, omission or misrepresentation in the information. Recommended citation Prescribing drugs of dependence in general practice, Part B – Benzodiazepines. Melbourne: The Royal Australian College of General Practitioners, 2015. Published by The Royal Australian College of General Practitioners 100 Wellington Parade East Melbourne Victoria 3002 Australia Tel 1800 473 247 Fax 03 8699 0400 www.racgp.org.au ISBN 978-0-86906-430-6 Published June 2015 © The Royal Australian College of General Practitioners, 2015. We recognise the traditional custodians of the land and sea on which we work and live. Prescribing drugs of dependence in general practice, Part B Benzodiazepines i Foreword Benzodiazepines have a chequered clinical history and continue to produce polar opinions in the medical community. Benzodiazepines have been associated with both benefits and harms for patients, and a clear guide for accountable prescribing has been requested from multiple agencies. Drug therapies will only ever have a partial role in managing complex bio-psychosocial issues that characterise mental health care. In the modern health environment, we have to explore and use non-drug therapies, and redefine the place of existing medications. This guide represents a synthesis of the best available evidence for benzodiazepine use in the primary care setting. Consistent with all medications, prescribing benzodiazepines requires clear patient selection and ongoing clinical monitoring to optimise outcomes. The risk–benefit ratio of benzodiazepines changes considerably with concomitant psychoactive drugs, or comorbid alcohol or substance abuse or misuse. In completing this guide, we acknowledge the work of the key advisers and reviewers, and the many people who have provided constructive feedback. The Royal Australian College of General Practitioners (RACGP) welcomes feedback on this guide to continually improve services at the general practice level. Please use the feedback section on our website to help co-create this guide. Prescribing drugs of dependence in general practice, Part B ii Benzodiazepines Acknowledgements The RACGP gratefully acknowledges the generous contribution of the following authors and reviewers of the RACGP’s Prescribing drugs of dependence in general practice, Part B – Benzodiazepines. Clinical editor Dr Evan Ackermann, Chair, RACGP National Standing Committee for Quality Care; University Medical Centre, Southern Cross University, Queensland Medical writer Raquel Newman Reviewers Dr Caroline Johnson, Department of General Practice, the University of Melbourne, Victoria; RACGP National Standing Committee for Quality Care Dr Simon Holliday, General Practitioner, Taree, New South Wales; Staff Specialist, Drug and Alcohol Clinical Services, Hunter New England Local Health District, New South Wales Dr Walid Jammal, Senior Medical Advisor, Avant; Clinical Lecturer, University of Sydney Dr John Buchanan, Consultant Psychiatrist, Melbourne Thank you to the following organisations, groups and individuals for feedback and advice: NPS MedicineWise Australian Medical Association RACGP National Standing Committee for Quality Care RACGP National Standing Committee for Standards RACGP National Standing Committee for General Practice Advocacy and Support RACGP Victorian Faculty, Drug and Alcohol Committee RACGP Queensland Faculty RACGP South Australia & Northern Territory Faculty RACGP National Faculty of Aboriginal and Torres Strait Islander Health RACGP National Rural Faculty RACGP National Faculty of Specific Interests – Addiction Medicine Network RACGP National Faculty of Specific Interests – Pain Management Network RACGP National Faculty of Specific Interests – Aged Care Network RACGP National Faculty of Specific Interests – Psychological Medicine Working Group Dr Beres Joyner, General Practitioner, Rockhampton, Queensland; RACGP National Faculty of Specific Interests – Aged Care Network Janet Shaw, Manager, Reconnexion, a Service of EACH, Victoria Dr Sara Bird, Manager, Medico-legal and Advisory Services, MDA National Dr Mike Civil, Chair, RACGP National Standing Committee for Standards Dr Jenny James, Substance Misuse Medical Coordinator, Aboriginal Medical Service Western Sydney Karen Booth, RN, President, Australian Primary Health Care Nurses Association Prescribing drugs of dependence in general practice, Part B Benzodiazepines iii Dr Mark E Montebello, Senior Staff Specialist and Medical Team Manager, Drug and Alcohol Service, South Eastern Sydney Local Health District Peter Boyles, Pharmaceutical Services Branch, Department of Health and Human Services, Tasmania Dr Adrian Reynolds, Clinical Director, Alcohol and Drug Service, Southern Mental Health and Statewide Services, Tasmania; Clinical Associate Professor, University of Tasmania Dr Noel Plumley, Addiction Medicine Specialist, Tasmanian Alcohol and Drug Services Dr Richard O’Regan, Addiction Medicine Consultant, Drug and Alcohol Office North Metro Community Drug Service, Department of Health, Western Australia Dr Chris Holmwood, Director, Clinical Consultation Liaison and Standards, Drug and Alcohol Services, South Australia Dr Stephen Christley, Public Health and Clinical Systems, Department for Health and Ageing, Government of South Australia Dr Adam Pastor, General Physician and Addiction Medicine Specialist; Director, Addiction Medicine, Northern Territory Dr Malcolm Dobbin, Senior Medical Advisor (Alcohol and Drugs), Mental Health, Drugs and Regions Division, Department of Health, Victoria Drugs of Dependence Unit, Pharmaceutical Services Branch, Department of Health, Western Australia Drugs of Dependence Unit, Medicines and Technology Policy and Programs, Department for Health and Ageing, South Australia Medicines and Poisons Control, Department of Health, Northern Territory Pharmaceutical Services Unit, Legal and Regulatory Services Branch, New South Wales Ministry of Health Medicines Regulation & Quality, Department of Health, Queensland Pharmacy Board of Australia Australian Health Practitioner Regulation Agency Consumers Health Forum of Australia The Royal Australasian College of Physicians Laureate Professor Nicholas J Talley, President, The Royal Australasian College of Physicians Brigitte Cusack, Program Officer, Medication Management, Eastern Sydney Medicare Local Dr Tim Senior, Chair, RACGP National Faculty of Aboriginal and Torres Strait Islander Health Dr Ronald McCoy, Education Strategy Senior Advisor, RACGP Dr Michael Wright, General Practitioner, RACGP National Standing Committee for General Practice Advocacy and Support Dr Andrew Byrne, General Practitioner, Redfern, New South Wales Dr Dennis Gration, General Practitioner, Belgrave, Victoria Dr John Scopel, General Practitioner, RACGP National Faculty of Specific Interests – Refugee Health Network Dr Glynn Kelly, Deputy Chair, RACGP National Standing Committee for Standards Dr Margaret Daley, Advisor, Medical Indemnity Protection Society Dr Genevieve Hopkins, General Practitioner, Red Hill, Queensland Dr Brendan Kay, General Practitioner, Warrnambool, Victoria Dr Michael Tan, General Practitioner, Blacktown, New South Wales Dr Paul Neeskens, General Practitioner, Board Member, RACGP Queensland Faculty Dr Cameron Loy, General Practitioner, Deputy Chair, RACGP Victorian Faculty Prescribing drugs of dependence in general practice, Part B iv Benzodiazepines Acronyms ADIS Alcohol and Drug Information Service ATODS Alcohol, tobacco and other drugs AUDIT Alcohol Use Disorders Identification Tool AWS Alcohol Withdrawal Scale CAS Clinical Advisory Service CBT Cognitive behavioural therapy CIWA-Ar Clinical Institute Withdrawal
Load more

Recommended publications
  • ICRC Duty of Care: Elements of Definition
    ICRC Duty of Care: elements of definition Definition “Duty of care” (DoC) is a legal concept that comes from common law and can be defined as a legal obligation requiring adherence to a standard of reasonable care while performing any acts that could foreseeably harm others. Another definition of DoC would be a legal obligation to act towards others with prudence and vigilance in order to prevent any risk of foreseeable damage. The (legal) consequence of a breach of such a duty is a legal liability imposed upon the author (of the breach) to compensate the victim for any losses they incur. DoC entails an obligation of means (obligation de moyens) as opposed to an obligation of result (obligation de résultat). This means that the author must take all appropriate measures and behave in an appropriate way in order to avoid causing harm to third parties. This being said, the fact that harm is done does not necessarily mean that the duty of care was breached (or, in other words that the author was negligent), as certain events are beyond the control of the author (because they were unforeseeable or unavoidable despite proper care being taken). The ICRC’s DoC obligations towards the defined population hence depend on the nature of the relationship between the ICRC and the concerned population (employees, accompanying dependents, Movement partners, external contractual partners) and the relevant (legal and contractual) provisions applicable to such relationship. Content The actual measure, scope or content of the “care” that is required in each situation depends primarily on two factors: (i) the relationship between the parties and (ii) the applicable law.
    [Show full text]
  • Substance Abuse and Dependence
    9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine.
    [Show full text]
  • GABA Systems, Benzodiazepines, and Substance Dependence
    Robert J. Malcolm GABA Systems, Benzodiazepines, and Substance Dependence Robert J. Malcolm, M.D. Alterations in the γ-aminobutyric acid (GABA) receptor complex and GABA neurotransmission influence the reinforcing and intoxicating effects of alcohol and benzodiazepines. Chronic modulation of the GABAA-benzodiazepine receptor complex plays a major role in central nervous system dysregulation during alcohol abstinence. Withdrawal symptoms stem in part from a decreased GABAergic inhibitory function and an increase in glutamatergic excitatory function. GABAA recep- tors play a role in both reward and withdrawal phenomena from alcohol and sedative-hypnotics. Although less well understood, GABAB receptor complexes appear to play a role in inhibition of moti- vation and diminish relapse potential to reinforcing drugs. Evidence suggests that long-term alcohol use and concomitant serial withdrawals permanently alter GABAergic function, down-regulate ben- zodiazepine binding sites, and in preclinical models lead to cell death. Benzodiazepines have substan- tial drawbacks in the treatment of substance use–related disorders that include interactions with alco- hol, rebound effects, alcohol priming, and the risk of supplanting alcohol dependency with addiction to both alcohol and benzodiazepines. Polysubstance-dependent individuals frequently self-medicate with benzodiazepines. Selective GABA agents with novel mechanisms of action have anxiolytic, anticonvulsant, and reward inhibition profiles that have potential in treating substance use and with- drawal and enhancing relapse prevention with less liability than benzodiazepines. The GABAB receptor agonist baclofen has promise in relapse prevention in a number of substance dependence dis- orders. The GABAA and GABAB pump reuptake inhibitor tiagabine has potential for managing alcohol and sedative-hypnotic withdrawal and also possibly a role in relapse prevention.
    [Show full text]
  • Benzodiazepines
    Benzodiazepines Using benzodiazepines in Children and Adolescents Overview Benzodiazepines are group of medications used to treat several different conditions. Some examples of these medications include: lorazepam (Ativan®); clonazepam (Rivotril®); alprazolam (Xanax®) and oxazepam (Serax®). Other benzodiazepine medications are available, but are less commonly used in children and adolescents. What are benzodiazepines used for? Benzodiazepines may be used for the following conditions: • anxiety disorders: generalized anxiety disorder; social anxiety disorder; post-traumatic stress disorder (PTSD); panic attacks/disorder; excessive anxiety prior to surgery • sleep disorders: trouble sleeping (insomnia); waking up suddenly with great fear (night terrors); sleepwalking • seizure disorders (epilepsy) • alcohol withdrawal • treatment of periods of extreme slowing or excessive purposeless motor activity (catatonia) Your doctor may be using this medication for another reason. If you are unclear why this medication is being prescribed, please ask your doctor. How do benzodiazepines work? Benzodiazepines works by affecting the activity of the brain chemical (neurotransmitter) called GABA. By enhancing the action of GABA, benzodiazepines have a calming effect on parts of the brain that are too excitable. This in turn helps to manage anxiety, insomnia, and seizure disorders. How well do benzodiazepines work in children and adolescents? When used to treat anxiety disorders, benzodiazepines decrease symptoms such as nervousness, fear, and excessive worrying. Benzodiazepines may also help with the physical symptoms of anxiety, including fast or strong heart beat, trouble breathing, dizziness, shakiness, sweating, and restlessness. Typically, benzodiazepines are prescribed to manage anxiety symptoms that are uncomfortable, frightening or interfere with daily activities for a short period of time before conventional anti-anxiety treatments like cognitive-behavioural therapy or anti-anxiety takes effect.
    [Show full text]
  • Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs
    Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs Douglas M. Ziedonis, M.D., M.P.H.; Joseph Guydish, Ph.D., M.P.H.; Jill Williams, M.D.; Marc Steinberg, Ph.D.; and Jonathan Foulds, Ph.D. Despite the high prevalence of tobacco use among people with substance use disorders, tobacco dependence is often overlooked in addiction treatment programs. Several studies and a meta-analytic review have concluded that patients who receive tobacco dependence treatment during addiction treatment have better overall substance abuse treatment outcomes compared with those who do not. Barriers that contribute to the lack of attention given to this important problem include staff attitudes about and use of tobacco, lack of adequate staff training to address tobacco use, unfounded fears among treatment staff and administration regarding tobacco policies, and limited tobacco dependence treatment resources. Specific clinical-, program-, and system-level changes are recommended to fully address the problem of tobacco use among alcohol and other drug abuse patients. KEY WORDS: Alcohol and tobacco; alcohol, tobacco, and other drug (ATOD) use, abuse, dependence; addiction care; tobacco dependence; smoking; secondhand smoke; nicotine; nicotine replacement; tobacco dependence screening; tobacco dependence treatment; treatment facility-based prevention; co-treatment; treatment issues; treatment barriers; treatment provider characteristics; treatment staff; staff training; AODD counselor; client counselor interaction; smoking cessation; Tobacco Dependence Program at the University of Medicine and Dentistry of New Jersey obacco dependence is one of to the other. The common genetic vul­ stance use was considered a potential the most common substance use nerability may be located on chromo­ trigger for the primary addiction.
    [Show full text]
  • The Effect of Opioids on Emotional Reactivity
    The Effect of Opioids on Emotional Reactivity Steven M. Savvas, BHSc (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences University of Adelaide August, 2013 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy i Steven M. Savvas, PhD Thesis, 2013 TABLE OF CONTENTS Abstract .................................................................................................................................... xi Declaration ............................................................................................................................ xiii Acknowledgements ............................................................................................................... xiv CHAPTER 1 - INTRODUCTION ...................................................................................... 1 1.1 OPIOIDS AND OPIOID MAINTENANCE TREATMENT ...................................... 1 1.1.1 A BRIEF HISTORY OF OPIOIDS .......................................................................... 1 1.1.2 OPIOID RECEPTORS ............................................................................................ 1 1.1.3 ADAPTATION TO OPIOIDS.................................................................................. 3 1.1.3.1 Tolerance ........................................................................................................ 4 1.1.3.2 Withdrawal ...................................................................................................... 4 1.1.3.3 Dependence
    [Show full text]
  • 2009/2010 Insurance Handbook Australian Underwater Federation
    ‘Private and Confidential’ 2009/2010 Insurance Handbook Australian Underwater Federation Inc. for the period 1st July 2009 to 1 st July 2010 Prepared by: OAMPS Insurance Brokers Ltd Level 2, 8 Gardner Close, Milton, QLD 4064 GPO Box 1113, Brisbane, QLD 4001 Phone: (07) 3367 5000 Fax: (07) 3367 5100 OAMPS Insurance Brokers Ltd ABN 34 005 543 920 Level 2, 8 Gardner Close, Milton QLD 4064 GPO Box 1113 Brisbane QLD 4001 T (07) 3367 5160 F (07) 3367 5100 E [email protected] W www.oamps.com.au Members & Affiliates Australian Underwater Federation Inc. and Affiliated Bodies We have pleasure in enclosing details of the AUF National Insurance Program for the 2009/2010 policy period. It is essential that each Club Executive advise all Members, Officials and Volunteers associated with them of this minimum level of Insurance cover. It must be clearly understood that after being informed of the level of cover taken out, it is an individual’s responsibility to ensure that he/she has adequate Insurance cover for his/her needs. In addition to these policies all players and officials may, and are encouraged to take out private health and income protection insurance. The 2009/2010 program benefits are outlined in detail in this Handbook. OAMPS Insurance Brokers services include professional advice on the complete range of general insurance products, we welcome the opportunity to assist you with all your insurance needs. Kind Regards Mathew Lethborg Senior Portfolio Manager OAMPS Insurance Brokers Ltd ABN 34 005 543 920 Level 2, 8 Gardner Close, Milton, Qld., 4064 Phone: (07) 3367 5145 Fax: (07) 3367 5100 Mobile: 0409 852 838 Email: [email protected] Web: www.oamps.com.au Page 1 Summary of Covers Cover under the Program consists of the following: 1.
    [Show full text]
  • Monitoring the Duty to Monitor
    Corporate Governance WWW. NYLJ.COM MONDAY, NOVEMBER 28, 2011 Monitoring the Duty to Monitor statements. As a result, the stock prices of Chinese by an actual intent to do harm” or an “intentional BY LOUIS J. BEVILACQUA listed companies have collapsed. Do directors dereliction of duty, [and] a conscious disregard have a duty to monitor and react to trends that for one’s responsibilities.”9 Examples of conduct HE SIGNIFICANT LOSSES suffered by inves- raise obvious concerns that are industry “red amounting to bad faith include “where the fidu- tors during the recent financial crisis have flags,” but not specific to the individual company? ciary intentionally acts with a purpose other than again left many shareholders clamoring to T And if so, what is the appropriate penalty for the that of advancing the best interests of the corpo- find someone responsible. Where were the direc- board’s failure to act? “Sine poena nulla lex.” (“No ration, where the fiduciary acts with the intent tors who were supposed to be watching over the law without punishment.”).3 to violate applicable positive law, or where the company? What did they know? What should they fiduciary intentionally fails to act in the face of have known? Fiduciary Duties Generally a known duty to act, demonstrating a conscious Obviously, directors should not be liable for The duty to monitor arose out of the general disregard for his duties.”10 losses resulting from changes in general economic fiduciary duties of directors. Under Delaware law, Absent a conflict of interest, claims of breaches conditions, but what about the boards of mort- directors have fiduciary duties to the corporation of duty of care by a board are subject to the judicial gage companies and financial institutions that and its stockholders that include the duty of care review standard known as the “business judgment had a business model tied to market risk.
    [Show full text]
  • A User's Guide to Methamphetamine
    A USER’S GUIDE TO METHAMPHETAMINE A self-help guide to reduce harm for people who use methamphetamine 1st Edition, March 2017 Acknowledgements This booklet was adapted from an original publication created by The National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. This information does not constitute medical advice. Please seek the immediate help of a qualified medical practitioner about any personal health concerns. This booklet is being distributed for information purposes only. In the current state of crisis related to crystal methamphetamine, this booklet is intended as a guide to reduce harm for people who use methamphetamine. It lists the most common features of methamphetamine use, ways to reduce harm associated with the use of meth, and strategies for cutting down and quitting. The best way to avoid problems with drugs is to not use them. We are grateful for the contributions of the Integrated Drug Strategies in Waterloo Region and Guelph Wellington, in particular the leadership of Adrienne Crowder and Lindsay Sprague. Don Roth, Kerry Manthenga, Shirley Hilton, and our community review team provided great support and helpful edits. Marcey Gray provided exemplary skill on the design, images and editing, with final expert assistance from Arkay Design and Print. We are thankful for the financial support to print copies from the Waterloo-Wellington Human Services and Justice Coordinating Committee. For more information please contact: Wellington Guelph Drug Strategy www.wgdrugstrategy.ca Waterloo Region Integrated Drugs Strategy www.waterlooregiondrugstrategy.ca Circulated with the support of: WaterlooRegion Integrated Drugs Strategy WaterlooRegion Integrated Drugs Strategy The best way to avoid problems with drugs is to not use them.
    [Show full text]
  • Module II Opioids
    Module II Opioids 101 Module II: Opioids 101 Module II is designed to introduce participants to basic facts about opioids, including information on pharmacology, acute and long-term effects, and basic information about treatments for opioid addiction. This module contains background information necessary to understand the role of buprenorphine in the opioid treatment system. If the audience is already highly knowledgeable about opioid treatment, this module should be abbreviated or omitted. Slide 1: Title Slide Slide 1 The next module provides an overview of opioids and opioid treatment, setting the stage to see the role of buprenorphine in the treatment system. Slide 2: Goals for Module II Slide 2 We are now going to turn a little more directly to the issue of opioid addiction. This module reviews the following: Opioid addiction and the brain Descriptions and definitions of opioid agonists, partial agonists and antagonists Receptor pharmacology Opioid treatment options Page 62 Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals Slide 3: Opiate/Opioid: What’s the Difference? Slide 3 Throughout this training we are using the term opioid to define the class of drug with which we are dealing. It is important to understand what this term means. Opiate refers only to drugs or medications that are derived directly from the opium poppy. Examples include heroin, morphine, and codeine. Opioid is a broader term referring to opiates and other synthetically-derived drugs or medications that operate on the opioid receptor system and produce effects similar to morphine. Examples include methadone, buprenorphine, meperidine, and fentanyl. Note to the Trainer(s): All opiates are opioids, but not all opioids are opiates.
    [Show full text]
  • The Legal Duty of a College Athletics Department to Athletes with Eating Disorders: a Risk Management Perspective Barbara Bickford
    Marquette Sports Law Review Volume 10 Article 6 Issue 1 Fall The Legal Duty of a College Athletics Department to Athletes with Eating Disorders: A Risk Management Perspective Barbara Bickford Follow this and additional works at: http://scholarship.law.marquette.edu/sportslaw Part of the Entertainment and Sports Law Commons Repository Citation Barbara Bickford, The Legal Duty of a College Athletics Department to Athletes with Eating Disorders: A Risk Management Perspective, 10 Marq. Sports L. J. 87 (1999) Available at: http://scholarship.law.marquette.edu/sportslaw/vol10/iss1/6 This Article is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. For more information, please contact [email protected]. THE LEGAL DUTY OF A COLLEGE ATHLETICS DEPARTMENT TO ATHLETES WITH EATING DISORDERS: A RISK MANAGEMENT PERSPECTIVE BARBARA BIcKFoRD* I. INTRODUCTION In virtually every college athletics department across the United States, there is an athlete with an eating disorder engaged in intercollegi- ate competition. Progressively larger proportions of eating disordered women have been identified in the general population and in college student populations, and they clearly have an analogue in the athletic sphere.' Knowledge of eating disorders in athletics populations has ex- isted for almost twenty years, yet many colleges and universities seem to be ignoring the problem.2 Eating disorders are a serious health threat that require prompt medical attention. Colleges may owe some duty of care to their athletes, in fact a college that ignores eating disorders may be negligent. To prevent legal liability, colleges and universities must educate their employees to be aware of and recognize symptoms of eating disorders, create a plan for interven- tion and treatment or referral, and engage in preventative education.
    [Show full text]
  • Community Services and Long-Term Care
    U.S. Department of Health and Human Services Assistant Secretary for Planning and Evaluation Office of Disability, Aging and Long-Term Care Policy COMMUNITY SERVICES AND LONG-TERM CARE: ISSUES OF NEGLIGENCE AND LIABILITY 1982 Office of the Assistant Secretary for Planning and Evaluation The Office of the Assistant Secretary for Planning and Evaluation (ASPE) is the principal advisor to the Secretary of the Department of Health and Human Services (HHS) on policy development issues, and is responsible for major activities in the areas of legislative and budget development, strategic planning, policy research and evaluation, and economic analysis. ASPE develops or reviews issues from the viewpoint of the Secretary, providing a perspective that is broader in scope than the specific focus of the various operating agencies. ASPE also works closely with the HHS operating divisions. It assists these agencies in developing policies, and planning policy research, evaluation and data collection within broad HHS and administration initiatives. ASPE often serves a coordinating role for crosscutting policy and administrative activities. ASPE plans and conducts evaluations and research--both in-house and through support of projects by external researchers--of current and proposed programs and topics of particular interest to the Secretary, the Administration and the Congress. Office of Disability, Aging and Long-Term Care Policy The Office of Disability, Aging and Long-Term Care Policy (DALTCP), within ASPE, is responsible for the development, coordination, analysis, research and evaluation of HHS policies and programs which support the independence, health and long-term care of persons with disabilities--children, working aging adults, and older persons.
    [Show full text]